NCT03834662 2024-11-19
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Bristol-Myers Squibb
Phase 1 Completed
Clinical Trials
9 trialsNCT03192345 2024-08-07
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT02252211 2022-10-12
LUD2014-002
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01515306 2022-03-08
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01457118 2021-07-12
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Nektar Therapeutics
Phase 2 Completed
NCT03009214 2021-05-10
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
amcure GmbH
Phase 1 Completed
NCT00836888 2020-10-08
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT03553108 2020-10-01
IVIVC
AstraZeneca
Phase 1 Completed
NCT01567163 2014-10-16
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed